Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Mirum Pharmaceuticals Q3 2026 Results: Net Loss of $40.8M

Mirum Pharmaceuticals reported a significant net loss of $898.1 million for the nine months ended September 30, 2026, primarily driven by $756.2 million in acquired in-process research and development expenses. Despite the loss, net product sales grew to $521.8 million for the same period, up from $372.4 million in the prior year.

Watch the Mirum Pharmaceuticals, Inc. earnings callFull call on the ALFA USA YouTube channel
Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue185.7133.0
Profit before tax-40.22.6
Net income-40.82.9
EPS (diluted, $ a share)$-0.87$0.05

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+39.6%
Operating margin-32.2%
Source

10-Q filed with the SEC, NASDAQ: MIRM. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Mirum Pharmaceuticals, Inc.: key numbers

Share price
$91.58Close, Nov 16
Market cap
$5.98B
Shares outstanding
65.28MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Mirum Pharmaceuticals, Inc.

All →
4:55 PM ET Form 4
Insider Selling

Mirum Pharmaceuticals Director Laura Brege Sells $1.33M of Stock

Laura Brege, Director, sold 14,167 shares of Mirum Pharmaceuticals, Inc. at $94.05 to $94.74 a share (average $94.21) in 2 transactions, worth $1.33M in total on Nov 11, 2026. Shares held after the trade: 15,703 (-17.2%).

Value
$1.33M
Shares
14,167
Average price
$94.21
Role
Director
Holding change
-17.2%
Trade date
Nov 11, 2026
7:42 AM ET 8-K
Clinical Trial Data

Mirum Pharmaceuticals Clinical Trial Data

Mirum Pharmaceuticals announced that its Phase 3 AZURE-4 study of brelovitug met its primary endpoint in patients with chronic hepatitis delta virus (HDV). The study showed that 59% of patients on the 300 mg weekly dose achieved the combined endpoint of virologic response and ALT normalization compared to 0% in the delayed-treatment arm. This data, alongside results from the AZURE-1 study, will form the basis of the company's U.S. registration package for brelovitug.

8:47 PM ET Form 4
Insider Selling

Mirum Pharmaceuticals CEO Christopher Peetz Sells $1.8M of Stock

Christopher Peetz, CEO, sold 20,000 shares of Mirum Pharmaceuticals, Inc. at $90.00 a share, worth $1.8M in total on Nov 4, 2026. Shares held after the trade: 206,637 (-8.8%).

Value
$1.8M
Shares
20,000
Price
$90.00
Role
CEO
Holding change
-8.8%
Trade date
Nov 4, 2026
4:04 PM ET 8-K
Financial Results

Mirum Pharmaceuticals Financial Results

Mirum Pharmaceuticals reported Q3 2026 net product sales of $185.7 million, driven by strong performance from LIVMARLI and Bile Acid Medicines. The company increased its full-year 2026 net product sales guidance to a range of $715 million to $720 million following the FDA approval and launch of ATEBRIOZ for FOP.

“The third quarter was an important period of execution for Mirum, with the approval and launch of ATEBRIOZ and positive Phase 3 results across our late-stage rare liver portfolio. Positive results from AZURE-1 and additional data we’ll be sharing at AASLD reinforce the potential of brelovitug to become an important new treatment for chronic HDV, while EXPAND results support the potential to bring LIVMARLI to more patients living with rare cholestatic liver diseases, including biliary atresia.”

Chris Peetz, Chief Executive Officer of Mirum
4:47 PM ET 8-K
Clinical Trial Data

Mirum Pharmaceuticals Clinical Trial Data

Mirum Pharmaceuticals announced positive results from Cohort 2 of its pivotal PROGRESS study evaluating ATEBRIOZ (zilurgisertib) in pediatric patients aged 6 to <12 with fibrodysplasia ossificans progressiva (FOP). The study met its endpoints with a significant reduction in total heterotopic ossification lesion volume and improved joint mobility compared to placebo, supporting a planned sNDA submission in the first half of 2027.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.